Search results
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
Missouri Independent via Yahoo News· 6 days agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
How AI Is Revolutionizing Drug Development
The New York Times via Yahoo News· 6 days agoMONROVIA, Calif. — The laboratory at Terray Therapeutics is a symphony of miniaturized automation. Robots whir, shuttling tiny tubes of fluids to their...
Phantom Cell Lines Undermine Cancer Research Credibility
Medscape· 5 days agoThis superficiality was illustrated by an image, created by artificial intelligence, of a mouse with...
16 Firming Serums Dermatologists Say To Use Daily To Tighten Skin, Hydrate, And Restore A Youthful...
SheFinds via Yahoo News· 17 hours agoSummer is well and truly here, which means we are all striving for the ultimate summer glow. We’ve...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 4 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks via Yahoo Finance· 2 days agoARQT is focused on developing and commercializing treatments for unmet needs in immune-mediated...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Up 11.1% in May
ETF DAILY NEWS· 4 days agoArcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling ...
AbbVie (NYSE:ABBV) Given New $190.00 Price Target at Piper Sandler
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Get Free Report) had its price objective boosted by research analysts at Piper Sandler from $185.00 to $190.00 in a research note issued on Tuesday, Benzinga reports. Piper ...
Johnson & Johnson (NYSE:JNJ) Position Boosted by PVG Asset Management Corp
ETF DAILY NEWS· 6 days agoPVG Asset Management Corp lifted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 28.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 4 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...